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Summary.-Biochemical characterization ofserologically detected human melanoma
antigens was undertaken for the development of immunodiagnostic assays in
melanoma. An antiserumfrom ahuman melanomapatient, whichdetected melanoma
antigens expressed on a large proportion of different melanoma cells, was used in
leucocyte-dependent cytotoxic antibody (LDA) 51Cr-release assays to monitor the
purification of melanoma antigens in urea/acetate extracts of lactoperoxidase
1251-labelled melanoma cell membranes. The separation procedures included
affinity chromatography on Concanavalin A, gel filtration on porous polyacrylamide
beads and preparative isoelectric focusing. The fractions were also monitored by
polyacrylamide electrophoresis in sodium dodecyl sulphate and by measurement of
32 microglobulin and carcinoembryonic antigen content.
The antigens detected by this antiserum appeared to be acidic (pl 35) low-mol.-wt
glycoproteins of , 15,000 daltons which were resistant to heating at56°C and digestion
with neuraminidase, but susceptible to repeated freeze-thawing and trypsin diges-
tion. They did not appear to be related to HLA antigens, 32 microglobuln or known
foetal antigens. The nature ofthe antigens detected inthese studies is asyetunknown,
but they appear similar to those described inthe sera andurine ofmelanomapatients
in previous reports. These combined results and the frequent expression of these
antigens on melanoma cells from different patients suggest that assays to detect this
antigen may provide a valuable immunodiagnostic aid in the management of
melanoma.
ANTIBODIES to antigens on melanoma
cells have been detected in the sera of
melanoma patients by a variety of
methodssuchasimmunofluorescence (Mor-
ton et at., 1968; Lewis et al., 1969; Lewis,
1972; Nairn, 1972; The et al., 1975),
complement-mediated cytotoxicity (Bod-
urtha et al., 1975) immune adherence
(Seibert et al., 1977; Cornain et al., 1975;
Shiku et al., 1976, 1977) and leucocyte-
dependent cytotoxic antibody (LDA) as-
says (Hersey et at., 1976, 1978a; Kodera &
Bean, 1975; Vanwijck et al., 1975).
However, the nature of the antigens
detected by the human antisera in these
studies is unknown. In some instances the
antigens appeared specific for each indi-
vidual (Lewis et al., 1969; Lewis, 1972;
Bodurtha et at., 1975; Shiku et at., 1976,
1977) whereas, in other studies, several
different antigens showing partial cross-
reactivity between melanoma cells from
different patients were detected (Hersey
et al., 1976; Seibert et al., 1977; Carey
et al., 1976; Shiku et al., 1976, 1977).
The aim of this study was to define the
biochemical nature ofsome ofthe antigens
detected by human antisera on melanoma
cells in the belief that this information
mightprovide some understanding oftheir
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biological nature and assist in the develop-
ment of immunodiagnostic assays. The
antigen selected for study was that
detected by a human antiserum which
showed partial cross-reactivity with a
large proportion of melanoma cells. Our
results indicate that the antigens detected
by this antiserum appeared to be low-
mol.-wt acidic glycoproteins of 15,000
daltons which were separable from HLA
and foetal antigens on the cell surface.
They appeared similar to those previously
detected in sera and urine of melanoma
patients (Murray et al., 1978) and we con-
sider that assays to detect this antigen
may provide a useful immunodiagnostic
aid in melanoma.
MATERIALS AND METHODS
Antisera.-The serum Ch used to charac-
terize the melanoma antigen in these studies
was obtained from a 66-year-old woman with
a long history of multiple local recurrences
in her leg. These dated from shortly after
removal of the primary melanoma 4 years
previously, and her leg was eventually
amputated 3 years after removal of the pri-
mary to control the local recurrences. The
serum was obtained just before the clinical
detection of disseminated melanoma in her
liver.
Antisera to /2 microglobulin (f2M) and
carcinoembryonic antigen (CEA) were from
Dako (Copenhagen) and were used after
absorption on human RBC and pooled human
platelets respectively. Serum AE from a
normal multiparous woman and JT from a
female melanoma patient have been described
previously (Hersey et al., 1976). Sera Tit. and
HI were from male melanoma patients and
Jay from a female melanoma patient. They
reacted with the MM200 line (see below) but
not with cells from the non-melanoma cell
lines used in this study. Sera Har and Joy
were from patients with carcinoma of bladder
and breast respectively. They reacted with
the corresponding cell lines used in this study,
but not with the other cell lines, including the
melanoma cell lines. Mac was a serum from a
patient with colon carcinoma, and was kindly
supplied by Dr Nind of the Department of
Pathology and Immunology, Monash Univer-
sity.
Melanoma LDA assays and measurement of
factors blocking melanoma LDA. The pro-
cedures involved in detection of melanoma
LDA by 51Cr-release assays, and the use of
these assays to measure blocking factors
against the melanoma LDA, have been fully
described in several recent publications
(Murray et al., 1977, 1978; Hersey et al.,
1978a).
In brief, 50 [lI of the sensitizing antiserum
at an appropriate dilution and 50 1I of the
cell-membrane fraction in saline in 10-fold
dilutions were added to 12 x 75mm round-
bottomed plastic tubes (Filtrona, Melbourne).
3 x 103 5lCr-labelled target cells in 200,ul
of RPMI+10% foetal bovine serum (FBS)
and 3 x 105 effector cells in 200 ,lI RPMI+
10% FBS were added, and incubated over-
night at 37°C. Effector cells were obtained
by centrifugation of defibrinated venous
blood from normal laboratory volunteers on
Hypaque-Ficoll mixtures.
In all assays the samples being tested for
LDA blocking were also added to cultures
without sensitizing LDA to determine the
effect, if any, on the natural killing activity
ofthe effector cells. The level ofnaturalkilling
in the presence of the test samples was taken
as the baseline for measurement of LDA
activity. Blocking of LDA activity was esti-
mated by comparison of the per cent 51Cr
release due to LDA in the absence and pre-
sence of the sample being tested for LDA
blocking. The titre ofLDA blocking was taken
as the last dilution giving a 5%o reduction in
5ICr release. This level of 51Cr release was
more than 2 standard deviations from the
points concerned, and was taken as the mini-
mum definite evidence for LDA blocking.
Melanoma cells.-These were principally
from the MM200 line established in culture
from a primary melanoma in the Queensland
Institute of Medical Research (Parsons et al.,
1974). Previous studies showed these cells
had surface antigens detected by a high pro-
portion of antisera from melanoma patients
(Hersey et al., 1976). Foetal antigens of un-
defined nature, CEA-like antigens and /2
microglobulin have been detected on these
cells (Hersey et al., 1976; Morgan et al., 1977).
The cells were grown in monolayers in RPMI
1640 supplemented with 20% FBS (Austra-
lian Laboratory Services, Batch 64).
Radioiodination of cell-surface macromole-
cules.-Radiolabelling of the melanoma cell-
surface molecules was carried out by lacto-
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peroxidase iodination procedures modified
from those described by Marchalonis et al.
(1971). MM200 cells were harvested after a
short exposure (5-10 min) to 0-25% trypsin.
They were then incubated at 37°C in RPMI
for 3-4 h to allow recovery of any surface
antigens removed by the trypsin. Aliquots of
4 x 106 cells were then washed 3 x in Hanks'
balanced salt solution (HBSS) and the cell
pellets resuspended in 100 [lI of phosphate
buffered saline (PBS) pH 7 3, containing
lactoperoxidase (Calbiochem B grade) at 500
Hug/ml. To this was added 3 Aul of Na125I
(Amersham, Bucks, England) and 10 ,ul of
H202 (3 mg/100 ml in PBS). The mixture was
agitated, incubated for 5 min at 23°C and
the addition of lactoperoxidase and H202
repeated. The reaction was stopped after 5
min by addition of cold PBS, and the cells
were then washed twice in 25 ml ofPBS.
Extraction of melanoma surface antigens by
urea/acetate. The radiolabelled cells were
resuspended in 1 ml of a mixture of 1OM
urea in 1P5M acetic acid (pH 4 8) as described
by Marchalonis et al. (1971) and incubated at
37°C for 2 h. The cells were then centrifuged
at 400 g for 15 min and the supernatant con-
taining the 1251-labelled proteins recovered
and dialysed twice against 11 ofPBS.
Affinity chromatography on Concanavalin A
(Con A).-The cell-membrane extract was
applied to Con A in a column 0-9 x 15 cm and
a graded elution procedure with ot-methyl
glueopyranoside (oMG) was used as described
fully in a previous report (Murray et al.,
1978).
Gel exclusion chromatography. This was
carried out on Biogel Ploo, 100-200 mesh and
on Biogel P30, 100-200 mesh (Bio-Rad
Laboratories) in 1-5 x 90cm columns (k 15/90
Pharmacia). The gel was prepared according
to manufacturer's instructions by hydration
in 0-IM EDTA in PBS (pH 5 2) at 90°C for
4h. The membrane extract was eluted in 0-1M
EDTA in PBS at a flow rate of 20 ml/h and
100 2ml samples were collected. Radioactivity
and UV absorbance of the fractions at 260
aind 280 nm were measured, and the fractions
were then pooled on the basis of the radio-
activity counts. The pooled fractions wvere
concentrated back to 2 ml in an Amicon
Diaflo cell using UM2 membranes. They were
then dialysed twice against 11 of PBS.
The column was calibrated with bovine
serum albumin, 68,000 dalton (Sigma) oval-
bumin, 43,000 daltons (Sigma) cytochrome C,
12,000 daltons (Sigma) and blue dextran
2000 (Pharmacia Fine Chemicals).
Polyacrylamide electrophoresis in sodium
dodecyl sulphate (PAGE-SDS). The method
described by Fairbanks et al. (1971) was used
as described previously (Murray et al., 1978)
using 100 x 6mm glass tubes and gels made
from 7-5% acrylamide and 0.30o methylene
bis acrylamide. Gels were sliced mechanically
into 2mm sections and counted in a gamma
counter. Mobility of radiolabelled peaks was
expressed relative to bromophenol blue.
Radiolabelling of melanoma antigen frac-
tions. Fractions from gel filtration were
labelled with 1251 by the chloramine T method
of Greenwood et al. (1963). 10-20 ,ug of the
fractions in 20 ,A were added to 1 mCi of
Na125J (Amersham, Bucks, England) and
10 [1 of chloramine T (2 mg/ml) for 60 s, then
20 ,ul of sodium metabisulphate (7-2 mg/ml)
was added to reduce unbound iodide. Free
1251 was removed by dialysis twice against
11 of 0.8% NaCl in 24 h.
Digestion of melanoma antigenfractions with
trypsin and neuraminidase.-Tryspin diges-
tion. 50 [I of the antigen fraction was incu-
bated with 50 ,ul of0.25% Trypsin (Difco) in
HBSS at 37°C for 60 min. 50 pA of FBS was
then added and the mixture used directly in
the melanoma LDA assays.
Neuraminidase digestion was carried out
using neuraminidase insolubilized on agarose
(Sigma N 5254) 0 03 unit (150 pul) was added
to 400 ,ul ofthe antigen fraction and incubated
with mixing at 37°C for 30 min. The super-
natant was then recovered after centrifuga-
tion and tested for inhibitory activity against
melanoma LDA.
Estimation of protein concentration.-This
was estimated by measurement of the UV
absorption of the sample at 260 and 280 nm
as described by Warburg & Christian (1941).
Insufficient material was available for protein
estimations by the Lowry method.
Preparative isoelectricfocusing. This was
carried out on a flat bed (Radola, 1974) in
Ultrodex (LKB) using LKB mcdel 2117
Multiphor equipment. In initial experiments
1 ml of the antigen fraction from the Biogel
P1oo or P30gel filtration was mixed with 2-5 ml
of ampholine, pH range 3-9, and 46-5 ml of
distilled water. 2 g of ultrodex was added to
this and the mixture placed on a flat glass
plate 30 cm by 3 cm. After nearly complete
evaporation a constant power of 2 W was
applied for 18 h. At this time a grid with 30
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spaces was applied, the pH of each section
measured and the antigen recovered from
each slice by several saline washes of the
ultrodex slices. After dialysis these were
concentrated on UM2 membranes in a 10 ml
Amicon cell and tested for melanoma LDA
blocking.
In subsequent studies 1 ml of the antigen
solution was run with ampholines over the
pH range 2-4, using the above conditions.
RESULTS
Specificity ofmelanoma antiserum Ch
The antiserum Ch was tested against a
number of cultured non-melanoma target
cells, cultured melanoma cells and primary
cultures of melanoma cells established
from melanomas removed at surgery. The
results of these assays are shown in Table
I in terms of LDA titres. As can be seen
there was no reaction with a large variety
of cultured non-melanoma target cells, all
of which showed susceptibility to killing
in LDA assays with appropriate antisera.
Assays against several different freshly
isolated carcinomas (breast (3) ovarian
(1) colon (1) and basal cell carcinoma (3))
were also negative.
The reaction against 1 of the 3 freshly
isolated breast carcinoma cells was weak
and seen only at a dilution of 1 in 10.
Repeat assays against this particular tar-
get cell were not possible with antisera
absorbed on foetal tissue, but previous
studies have shown that weak cross-
reactivity of this nature was removed
after absorption of the antisera on foetal
tissue. (Hersey et al., 1976.)
There was reactivity with 60% ofthe
26 primary cultures of melanoma cells,
which was consistent with the restricted
cross-reactivity of human melanoma anti-
sera noted in previous studies (Hersey
et al., 1976).
The specificity of the serum was also
assessed by absorption on 1 its volume of
foetal brain from a 16-20-week foetus,
foetal thymus and spleen from a 16-18-
week foetus and melanocytes from the
uveal tract of a freshly excised eye, for
30 min at 37°C and 1 h at 4°C. No reduc-
tion in titre was noted after these absorp-
tions. The serum was also passed over
/2 microglobulin (f2M) coupled to Sepha-
rose 4B and carcinoembryonic antigen
(CEA) (kindly supplied by Dr N. Hughes,
Prince of Wales Hospital, N.S.W.) bound
to Sepharose 4B. No reduction in titre was
found, whereas passage ofantisera against
/2M and CEA completely removed the
activity from equivalent amounts of sera.
Analysis of melanoma cell-membrane
extracts byaffinitychromatographyonConA
A dialysed urea/acetate cell-membrane
TABLE I.-Specificity of melanoma serum Ch in LDA assays
Reaction against
non-melanoma
target cells Reaction against melanoma target cells
,- I
Target
cell
Chang
tIMR32
HT29
T24
Det562
MCF-7
B,
PHA-Ly(4)
HL60
LDA Target
titre cell
0 *MM200
0 MM96
0 MM127
0 MM170
0 Odm
0 Jem
10-1 Mar
0 Sim
0 Pet
LDA
titre
10-3
10-1
0
10-2
10-2
0
10-2
0
10-3
Target
cell
Hos
Nug
Bur
Bro
A33
Ikn
Woo
Sims
Law
LDA
titre
10-1
10-3
10-3
0
0
10-3
10-3
10-1
10-'
Target
cell
Tod
Sho
Fle
Hef
Pug
Hog
Cal
Kel
Bor
LDA
titre
10-3
0
10-3
0
10-2
10-2
10-3
10-3
0
* MM=Melanoma cell lines. Letters refer to individual patients.
t IMR32=neuroblastoma, HT29 = colon carcinoma, T24=bladder carcinoma, Det562=carcinoma of
pharynx, MCF-7 =breast carcinoma, HL60 =acute myeloid leukaemia, Bl =freshly isolated breast car-
cinoma, PH.A-Ly=phytohaemagglutinin transformed blood lymphocytes whose HLA phenotypes were as
follows: A2, 3, B7; Al, 2, B7,15; A24,31/30. B7,27; A2,11, B27,41.LOW-MOLECULAR-WEIGHT MELANOMA ANTIGENS
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FIo. 1.-Melanoma LDAblockingbyfractions
from Con A affinity chromatography of
melanomacell-membraneextract.Ex=urea/
acetate extract of MM200 cells. 0=fraction
not binding to Con A, and 5, 50 and 100
indicate fractions eluted at these concentra-
tions (mg/100 ml) of n-methyl gluco-
pyranoside (aMG). Blocking of melanoma
LDA is shown by original extract and frac-
tions eluted with 100 mg and 50 mg of
csMG. T=MM200 target cells alone. +E =
MM200+ 3 x 105 effector cells from normal
subject. +ab=MM200+effector cells+
melanomaAb, Ch, atafinaldilutionof1 :200.
S.e. < 2% *, with and 0, without antigen.
extract from 50 x 106 MM200 cells in 9 ml
was applied to 150 ml of Con A Sepharose
and eluted from the Con A with 0-5M
NaCl in HBSS containing 0, 5, 50 and
1-.
0: 8
co Cx
X._
4 ....
'I
40 60
100 mg of oaMG. These fractions and the
original extract were tested for their
melanoma LDA-neutralizing activity as
shown in Fig. 1. Blocking was seen to a
titre of at least 10-3 in the fraction eluted
with 100 mng ofaMG and 10-2in the 50mg
oxMG eluate. It may also be noted that
stimulation of cytotoxicity by the cells
used as antibody-dependent effector cells
was noted against the target cells in all
the fractions eluted with cxMG. In some
studies LDA blocking was seen in the non-
binding fraction (Con A-) but this was
removed by a second passage over the
Con A, and presumably was due to over-
loading the column. The above results
were consistent in 4 experiments. The
125I counts eluted with 100 mg (xMG
were 8-6, 14-5, 5-2 and 11% of the total
counts eluted in 4 experiments.
Gel chromatography of melanoma
antigenfractionfrom Con A affinity
chromatography
The elution profile of radiolabelled
100
t
E280
1cm
ELUTION VOLUME
FIG. 2.-"BioGel Ploo" filtration proffile of the 100mg ocMG eluate from Con A affinity chromato-
graphy of the 125I-labelled melanoma extract. E =excluded fraction, BSA, Ov, Ch and CC indicate
elution position of BSA (68,000 daltons), Ovalbumin (43,000 daltons), Chymotrypsinogen (25,700
daltons) and Cytochrome C (12,000 daltons). The 100 mg caMG eluate fractions were pooled into A,
B, B1, C, D and D1 and E as indicated. Mol. wts of B, C, D1 and E were 60,000, 35,000, 15,000
and 7,500 respectively.
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Con A 100mg on P100
*;9 7-_
A B B1 C D D1 E
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FIG. 3. LDA blocking by the gel-filtration fractions indicate(d in Fig. 2 against melanoma serum Clh.
Symbols as for Fig. 1. LDA blocking was most pronounced in the low-mol.-wt fractions D and Di1.
S.e. < 2%.
material from the BioGel Ploo column of
the 100mg cxMG eluate is shown in Fig. 2.
Major radiolabelled peaks were eluted
before and after that of cytochrome C
(12,000 daltons) with mol. wt of , 15,000
and 7500. Smaller peaks were eluted
between ovalbumin and chymotrypsin of
35,000 and close to BSA of
A small peak was present in the exclusion
volume. The 100mgoxMG fractions from
gel filtration were pooled as indicated in
the figure, into fractions referred to as
A,B,B1,C,D,D, and E. They were then
dialysed, concentrated back to the original
volume, applied to the column (8 ml) and
tested for blocking against melanoma LDA
ofCh, as shown in Fig. 3.
The low-mol.-wt Fractions D and D1
of the 100mg aoMG eluate had the most
pronounced blocking activity (titre greater
than 10-3) but weak blocking was also
seen in Fractions E and B. These results
were repeated on 4 occasions, and on each
occasion the major LDA blocking activity
was in the D fraction eluting before cyto-
chrome C. The main variations between
experiments were (1) the excluded Frac-
tion A had relatively more radiolabelled
counts in some experiments, (2) the LDA
blocking activity in Fractions A, B and
C varied from 0 to 10-1.
Further gel chromatography of the low-mol.-
wt fraction of mielanoma cell-membrane
extract
To more closely define the low-mol.-wt
fraction D1, 7 ml of this fraction was
applied to a Biogel P30 column, which
separated the material as shown in Fig. 4.
Peaks of radioactivity were seen at 15,000
and 30,000 and a small peakintheexcluded
fraction. The fractions were re-combined
into Fractions A, B, C and D as indicated,
dialysed, concentrated on UM2 mem-
branes and tested in LDA assays as shown
in Fig 5. This assay was carried out simul-
taneously with that shown in Fig. 3. The
major blocking activity was again in the
15,000 fraction (titre > 10-3) but small
amounts of LDA blocking were seen in all
fractions.
Characterization ofmelanoma cell-membrane
fraction8 by PAGE-SDS
In parallel with the separation proce-
dures and characterization by LDA
blocking described above the fractions
were analysed by PAGE-SDS. Represen-
tative results of these studies on fractions
obtained by gel filtration on Biogel P30
are shown in Fig. 6. A, B, C and D refer
to the fractions shown in Fig. 4. All frac-
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FiG. 4. Gel filtration profile of the low-mol.-wt fraction D1 from Biogel P1oo on P30. Radiolabelledi
peaks were seen predominantly at 15,000 and 30,000 daltons. The fractions were recombined into
fractions A, B, C, and D, as shown.
70
r.n
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40
P 100 D1 on P30
0 a
A B
0
Li.IL
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D
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RECIPROCAL DILUTION Log 10
FiG. 5.-LDA blocking by gel-filtration frac-
tions from BioGel P1oo. Blocking was
again predominantly in low-mol.-wt frac-
tion D. Symbols as for Fig. 1.
tions were relabelled with 1251 by the
chloramine T method.
In all instances in which the fraction had
LDAblockingactivity, a low-mol.-wt frac-
tion of 15,000 was detected in PAGE-SDS
with relative mobility of 0-85 migrating
close to cytochrome C (relative mobility
0.925). This is most clearly seen in Fig.
6D. Fractions without LDA blocking
activity did not have peaks with this
mobility. A lower-mol.-wt factor was
usually detected with similar mobility to
cytochrome C, but this did not correlate
with LDA blocking. Similarly, fractions
with mobility close to 0-7 (25-30,000) and
0 45 (- 60,000) were evident but showed
a variable correlation with LDA blocking.
Specificity of LDA blocking activity of the
melanoma antigen fraction
The low-mol.-wt Fraction D from the
Biogel Ploo fraction was tested in LDA
assays against MM200 using a variety of
melanoma and non-melanoma antisera.
The results in Table II indicate that LDA
activity of anti /2M and CEA and anti-
HLA-A 11 against MM200 target cells was
not inhibited. This also applied to the
antiserum AE from a normal subject,
which, as previously shown, appeared to be
directed to foetal antigens (Hersey et al.,
1976). The fractions did, however, inhibit
the LDA activity of a number of antisera
from melanoma patients as shown in the
table. The specificity of the fraction was
further assessed by addition to LDA
assays against a number ofnon-melanoma
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FIG. 7.-Characterization of the BioGel P30
"D" antigen fraction by isoelectric focusing
in Ultrodex, using ampholines over the pH
range 2-4. LDAblockingwaspredominantly
focused at pH 3-5 and pH 2-5. CMC=cell-
mediated cytotoxicity.
with the corresponding carcinomas. They
all had titres of 102-103. The anti-HLA-A
II antiserum was from a male patient
bearing a renal homograft and had a titre
of 10-2. The melanoma antigen fraction
did not block the LDA activity of these
sera.
LDA blocking by antigen extract from
bladder-carcinoma cell line
As a further check of the specificity of
the antigen fraction, 50 x 106 T24 bladder
carcinoma cells were extracted with urea/
I acetate and processed to the Biogel Ploo
*2 .4 6 8 1.0 stage. A low-mol.-wt fraction equivalent
to the D fraction seen in the Biogel Ploo
RELATIVE MOBI LI TY profile of the melanoma extracts was not
PAGE-SDS profiles ofthe melanoma seen in the bladder-carcinoma extracts.
fmbrane fractions obtained by gel The Con A 100mg oxMG eluate of the
)n of Ploo D1 fraction of BioGel
SA, Ov, Ch and CC as in Fig. 2. bladder carcinoma extract was therefore
text for description and Fig. 5 for used to test if this fraction contained
locking activity ofthe corresponding material which would block the antiserum
nis.
Ch in LDA assays against the MM200
ls sensitized with LDA specific to target cell. As shown in Table II, no block-
t cell. These are also indicated in ing activity was detected against this
The antisera against the car- antiserum, but it did block the LDA
3IIlines were from humanpatients activity of an antiserum from a bladder-
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TABLE II.-Specificity ofLDA blocking by melanoma antigenfraction
Sensitizing
antisera
Anti fl2M
,, 9 Anti CEA
,,1 JT*
,, 31 Jay*
,, 11 Tit*
,, 9 AE
Ch*
,, 9 Cht
,, Anti-HLA-A II
LDA
blocking
titre
0
Target
cell
Chang
0 T24
T24t
102 HT29
0 MCF-7
103 PHA-Lym
0
103
0
0
Sensitizing
antisera
Rabbit
anti-Chang
Harl
Hart
Mact
Joy$
Anti-HLA-A II
See Table I for Codes to cell lines used.
* Antisera from melanoma patients.
t Addition ofantigen from T24 bladder-carcinoma cells.
t Antisera from patients with carcinoma corresponding to origin of cell line.
Target cells were sensitized with the lowest dilution of the antiserum giving maximal cytotoxicity against
target cells.
carcinoma patient against the T24 bladder-
carcinoma cell line.
Assays of melanoma antigen extracts for
f2M and CEA
The urea/acetate extract of 50 x 106
MM200 cells, and the Con A 100mg oaMG
eluate were assayed by commercial radio-
immunoassays for 32M and CEA. A CEA
concentration of 4-2 ng/ml and a 32M
concentration of 10 ,tg/ml were detected
in the original extract. Less than 0 4 ng/ml
of CEA was detected in the 100mg oaMG
eluate. No 32M was detectable in the
Biogel Ploo fractions.
Stability tophysical and enzymatic agents
The low-mol.-wt fraction D from the
Biogel Ploo gel filtration procedure was
subjected to freeze-thawing x 3, heating
to 56°C and 95°C for 30 min and digestion
with Trypsin and Neuraminidase as des-
cribed. The treated and untreated frac-
tions were then tested for LDA blocking
in assays of serum Ch against the MM200
target cell. The results indicated that the
antigen fraction was resistant to heating
to 56°C for 30 min and digestion with
neuraminidase, but was susceptible to
freeze-thawing, heating to 95°C and diges-
tion with trypsin. Similar results were
obtained in 2 experiments with successive
42
D fractions from the BioGel 100 filtration
procedure.
Analysis of the low-mol.-wt fraction by
isoelectric focusing
In preliminary experiments using am-
pholines over the range pH 3-9 the LDA
blocking activity of the low-mol.-wt frac-
tion D from the BioGel P30 column was
found to focus at the pH 3*5-3-8 end ofthe
bed. The BioGel P30 fraction was therefore
run subsequently in ampholines over the
pH range 2-4. The results shown in Fig. 7
indicate that the LDA blocking activity
localized mainly at the pH range 3*45-
3 55, but that smaller amounts were also
detected at the pH range 2-45-2-55.
Stimulation of cytotoxicity by the effector
cells was noted at the pH range 2-3-2*4
and 3-3-3-6. When the LDA blocking
fraction localizing at pH 3-5 was re-run on
PAGE-SDS, radiolabelled peaks were
noted at 15, 30, 45 and 60,000 daltons.
Percentage recovery of 125I counts ap-
proached 90%. The fraction with LDA
blocking activity localizing at about pH
3-5 in this study accounted for 22% ofthe
counts recovered.
DISCUSSION
The nature of the antigen detected by
this antiserum is unknown. It appeared to
Target
cell
MM200
LDA
blocking
titre
0
0
103
0
0
0
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be expressed on a high proportion (60%)
of melanoma cells taken from surgical
specimens, and was presumably similar to
antigens showing partial cross-reactivity
between different melanoma cells des-
cribed in previous studies (Hersey et al.,
1976; Shiku et al., 1976; Seibert et al.,
1977). The antiserum did not react with
a large variety of cell lines established
from several different carcinomas or other
malignancies. Tests against PHA-trans-
formed lymphocytes expressing a variety
ofHLA antigens were also negative. These
results suggest the antiserum was not
detecting HLA antigens, antigens asso-
ciated with tissue cultures or foetal anti-
gens common to carcinomas, lymphoid or
haemopoietic malignancies. Absorption
on foetal brain, thymus and spleen cells
or CEA bound to sepharose did not cause
loss of activity, which also argued against
the specificity of the antiserum being
directed to foetal antigens.
Greaves & Janossy (1978) reported that
some antigens thought to be tumour-
associated antigens on acute lymphatic
leukaemia cells were instead differentiation
antigens. Absorption of the antiserum
used in this study on melanocytes from
the uveal tract ofa freshly excised eye ofa
foetus or adult, did not remove significant
amounts of LDA activity against
melanoma cells. This result argued against
the antigen detected being a melanocyte
differentiation antigen, but we cannot
exclude that it may be expressed by
melanocytes at different stages ofdifferen-
tiation from that used in these studies.
The use ofLDA assays to define antigen
could be questioned, in that it is possible
for the effector cells in the assay to be
inhibited non-specifically by toxic com-
ponents in the membrane fractions. This
was one of the reasons for the use of urea/
acetate for the extraction procedure, since
it was easier to remove than detergents
such as NP40 and Triton X100. In pre-
liminary experiments, the titre of LDA
blocking activity obtained by urea/acetate
was found comparable to that ofNP40 and
Triton X100.
The specificity of the LDA blocking for
melanoma antigens was shown by addition
of the fraction to assays of various sera
against the MM200 target cell and a
variety of non-melanoma target cells. The
results indicated that it was only the
melanoma antisera that were inhibited
by the melanoma antigen fraction. In
particular, antisera to HLA antigens and
32M, and a human antiserum to foetal
antigens on the melanoma cell, were not
inhibited by the antigen fraction. Con-
versely, an antigen fraction from cultured
bladder-carcinoma cells did not inhibit
melanoma LDA, but did inhibit LDA
to bladder-carcinoma cells. The results
indicated that the blocking seen was
not due to non-specific blocking of the
effector cell but was specific for the
antigen detected by the antiserum in the
assays.
The methods used in these studies were
adapted from those used previously to
characterize a factor in the sera of mela-
noma patients which blocked melanoma
LDA activity (Murray et al., 1977; 1978).
Affinity chromatography on Con A proved
to be the most useful single procedure in
purification of the antigen, and also pro-
vided evidence that it was a mannose-
and/or glucose- containing glycoprotein.
The subsequent gel filtration steps on
polyacrylamide beads indicated that the
antigen-containing fractions were 15,000
mol. wt. It should be noted that the
results ofgelfiltrationwith polyacrylamide
beads were highly reproducible, but were
less so with Sephadex G50 or G100. This
may have indicated interaction of the
material with the Sephadex. Fractions of
, 15,000 mol.-wt were also seen in the
PAGE-SDS studies and could be corre-
lated with the LDA blocking activity of
these fractions. PAGE-SDS studies of the
15,000 mol.-wt fraction consistently
showed peaks at 30,000 and 60,000, which
suggested that the antigenic material may
have aggregated despite the use of SDS.
Similar explanations may account for the
localization of LDA blocking activity at
pH 3-5 and pH 2-5 by isoelectric focusing,LOW-MOLECULAR-WEIGHT MELANOMA ANTIGENS
or this may represent two different anti-
gens.
The antigenic activity appeared to be
lost after digestion with trypsin or freeze-
thawing, which suggested that the protein
component formed part of the antigenic
determinants ofthe molecule. Therewasno
loss of activity after digestion with neur-
aminidase, which indicated that terminal
sialic acid did not form part of the
antigenic determinants. A more compre-
hensive study using different glycosidases
is, however, required before the role ofthe
glycoside component in the antigenicity
of the molecules can be assessed.
There is now considerable diversity of
opinion in the literature on the bio-
chemical nature of melanoma antigens,
which to a large degree may be a reflection
of the different methods used to charac-
terize the antigens. Bystryn & Smalley
(1977) using double antibody precipitation
methods, indicated that the mol. wt ofthe
antigens was greater than 100,000. Similar
results had previously been obtained by
Viza & Phillips (1975) using crossover
electrophoresis to detect the melanoma
antigen. Both studies used antisera raised
in rabbits againsttheantigenpreparations,
and it is possible that the difference noted
in our studies may reflect the recognition
ofdifferent antigens on melanoma cells by
rabbits compared to humans.
Melanoma antigens producing delayed
skin-test responses were shown to be
glycolipoproteins by Hollinshead (1975)
and both high and low-mol.-wt proteins by
Roth et al. (1976). Jehn et al. (1970) found
melanoma antigens which induced lym-
phocyte transformation to be / globulins
of mol-wt < 40,000. Rather similar results
were obtained by Carrel & Theilkaes (1973)
in gel-diffusion assays.
Thomson et al. (1978) used leucocyte
adherence inhibition assays to characterize
papain extracts of melanoma cells, and
found the active fractions could be
resolved by gel filtration and PAGE-SDS
into several fractions with mol. wts of
12, 25 and 40,000. The low-mol.-wt
fraction was thought to be 82M and it
was postulated that tumour-associated
antigens might be associated with 32M.
The small 15,000 mol.-wt fraction in our
studies was unlikely to be /32M in that it
was consistently larger than /32M by gel
filtration and PAGE-SDS. /2M was not
detected by commercial radioimmuno-
assays of the purified antigen fractions,
which did not inhibit antisera to /2M
in LDA assays against the melanoma tar-
get cell. Our results also appear to exclude
association of melanoma antigen with
HLA antigens because the purified frac-
tions did not inhibit HLA antisera against
the MM200 target cell nor against blood
leucocytes. These results are similar to
those of McCabe et al. (1978) and Stuhl-
miller et al. (1978).
The latter authors found that melanoma
antigens could be detected in fractions
with mol.-wts of48,000, 25,000, 17,000 and
13,000 by inhibition of a chimpanzee anti-
serum to melanoma cells. All but the
13,000 fraction contained foetal antigens.
Our results support these findings of
melanoma antigens in low-mol.-wt frac-
tions of cell membrane extracts.
The low-mol.-wt fraction defined in
these studies is similar to that described
in sera ofmelanoma patients in a previous
report (Murray et al., 1978). In preliminary
studies it was also found that melanoma
LDA blocking activity in sera was related
to tumour growth (Hersey et al., 1978b).
We are therefore encouraged to believe
that the antigen fraction defined in these
studies is identical to that detected in the
circulation and urine of melanoma pa-
tients, and, in view of the common
expression of this antigen on melanoma
cells, monitoring of this fraction might
provide a valuable immunodiagnostic aid
in management of melanoma. The bio-
logical nature of the antigens detected in
this study and their importance in the
tumour relationship remain to be studied.
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